Trials / Completed
CompletedNCT04558385
Seroconversion in COVID-19 Recovered Population
Seroconversion in COVID-19 Recovered Population: an Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 275 (actual)
- Sponsor
- Lahore General Hospital · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study investigate the kinetics of IgG responses to both N and S proteins in the subjects who suffered from COVID 19 and then had recovered.
Detailed description
Coronaviruses (CoVs) are enveloped, single positive-strand RNA viruses belonging to the large subfamily Coronavirinae, which can infect mammals and several other animals.The continued spread of coronavirus disease 2019 (COVID-19) has prompted widespread concern around the world, and the World Health Organization (WHO), on 11 March 2020, declared COVID-19 a pandemic. Studies on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) showed that virus-specific antibodies were detectable in 80-100% of patients at 2 weeks after symptom onset. Currently, the antibody responses against SARS-CoV-2 remain poorly understood and the clinical utility of serological testing is unclear Little is known about the kinetics, tissue distribution, cross-reactivity and neutralization antibody response in COVID-19 patients . The seropositivity rate of both IgM and IgG responses after onset and recovery of disease, and in the context of both N protein and S protein has not been clarified. The kinetics of antibody responses in critical cases or ICU patients has not been reported, and no studies have suggested whether antibody response is associated with disease prognosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | IgG SARS CoV2 | IgG SARS CoV 2 will be checked in serum of COVID 19 recovered population |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
- First posted
- 2020-09-22
- Last updated
- 2021-04-01
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT04558385. Inclusion in this directory is not an endorsement.